<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="= 0.015). Conclusions The study confirms effectiveness and safety of DAA-based" exact="treatment" post="also in this special population, even if a careful"/>
 <result pre="of history and drug-drug interactions is warranted. Keywords HCV Antiviral" exact="treatment" post="SVR Psychiatric comorbidity Background Nowadays, it is estimated that"/>
 <result pre="[8]. Patients with such comorbidity have often been excluded from" exact="treatment" post="with Interferon (IFN)-based regimens because of the elevated risk"/>
 <result pre="the potential to close the gaps in the current DAA" exact="treatment" post="portfolio. Eight-twelve weeks of treatment is now the standard"/>
 <result pre="gaps in the current DAA treatment portfolio. Eight-twelve weeks of" exact="treatment" post="is now the standard of care and viral eradication"/>
 <result pre="comorbidity were defined as subjects who had received a previous" exact="diagnosis" post="by a psychiatric specialist and for whom a psychiatric"/>
 <result pre="purposes of analysis, patients were divided based on their psychiatric" exact="treatment" post="into two groups: subjects experienced with anxiolytic and/or antidepressant"/>
 <result pre="experienced with anxiolytic and/or antidepressant (group A) and subjects on" exact="treatment" post="with antipsychotic (group B). Demographic, clinical and biochemical data,"/>
 <result pre="well as their type and grade of severity. DAA-based anti-HCV" exact="treatment" post="The following regimens were administered based on international recommendations"/>
 <result pre="measured for all patients at baseline, at the end of" exact="treatment" post="(EOT), and 12 weeks after EOT (SVR-12), using the Siemens"/>
 <result pre="Healthcare Diagnostics, Tarrytown, NY, USA), with a lower limit of" exact="detection" post="of 15 IU/ml. HCV genotype and subtype were determined using"/>
 <result pre="EOT. Virological breakthrough was defined as an undetectable HCV-RNA during" exact="treatment" post="followed by a detectable HCV-RNA, despite continued treatment. Relapse"/>
 <result pre="(SD ±13.5), and 31.9% of them were cirrhotic. Patients in" exact="treatment" post="with antipsychotic drugs were younger (50.6 vs. 64.9 years, p"/>
 <result pre="(52.5% vs. 18.6%, p &amp;lt; 0.001). Failure to a previous anti-HCV" exact="treatment" post="was reported in 32 patients (22.2%), the majority among"/>
 <result pre="reported in 32 patients (22.2%), the majority among patients in" exact="treatment" post="with anxiolitycs and antidepressant (28.7% vs. 7.0%, p = 0.004)."/>
 <result pre="were HCV/HIV-coinfected. Coinfected patients were mostly represented among subjects in" exact="treatment" post="with antipsychotic drugs (23.3% vs. 8.9%, p = 0.030). Two"/>
 <result pre="prescribed DAA-regimen was SOF + VEL ± RBV (25.7% overall), especially in subjects in" exact="treatment" post="with antipsychotic (51.2% vs. 14.9%, p &amp;lt; 0.001). The regimen"/>
 <result pre="higher percentage of former drug users, were mostly on substitution" exact="treatment" post="with opioids at the time of inclusion in the"/>
 <result pre="Suicide attempted,n(%) 5 (3.5%) 2 (2%) 3 (7%) 0.157 Psychiatric" exact="treatment" post="modification before DAA treatment,n(%) 20 (13.9%) 11 (10.9%) 9"/>
 <result pre="episode-current manic episode-current hypomanic episode; Change of psychiatric and antiretroviral" exact="treatment" post="before DAAs-initiation Among the entire study population, a total"/>
 <result pre="= 0.349). Before the ART change, 5/6 (83.3%) patients were in" exact="treatment" post="with protease inhibitors: one with atazanavir unboosted, two with"/>
 <result pre="had received the SOF + DCV + RBV combination for 12 weeks; he had resistance" exact="testing" post="performed at failure which demonstrated a resistance pattern against"/>
 <result pre="group A (92%) which was mostly due to a higher" exact="prevalence" post="of patients lost to follow-up (6/43, 14% vs. 6/101,"/>
 <result pre="presented a higher rate of failure to a previous anti-HCV" exact="treatment" post="(47.0% vs 18.9%, p = 0.024). The proportion of patients"/>
 <result pre="who underwent a change of the psychiatric regimen before anti-HCV" exact="treatment" post="(6/20 patients, 30%) compared to those who maintained the"/>
 <result pre="no differences were observed according to ART change before anti-HCV" exact="treatment" post="(no patient failed among those changing ART before baseline"/>
 <result pre="Most AEs in course of DAAs occurred in patients in" exact="treatment" post="with anxiolytics and antidepressant (48.5% vs. 25.6%, p = 0.015)."/>
 <result pre="disorders (7.6%). Patients receiving RBV more frequently showed AEs during" exact="treatment" post="in comparison with subjects treated with RBV-sparing regimens. Erythropoietin"/>
 <result pre="anaemia in 3 patients (2.1%). Three hospitalizations (not leading to" exact="treatment" post="discontinuation) were reported due to: angina episode, hyperammonaemic encephalopathy"/>
 <result pre="hyperammonaemic encephalopathy and hematemesis. No death was reported. Discussion The" exact="treatment" post="of chronic hepatitis C virus infection has been revolutionized"/>
 <result pre="was reported. Discussion The treatment of chronic hepatitis C virus" exact="infection" post="has been revolutionized thanks to the recent development of"/>
 <result pre="increase the likelihood of cure with a shorter duration of" exact="treatment" post="and a better safety profile compared to previously used"/>
 <result pre="this &quot;special group&quot; can be attributed to concerns about poor" exact="treatment" post="adherence or pessimism regarding HCV-treatment tolerability and/or effectiveness even"/>
 <result pre="nowadays these patients are still lacking or delaying access to" exact="treatment" post="and cure. The coexistence of HCV-infection with cognitive disorders"/>
 <result pre="third of HCV-infected patients according to different studies [21–23], the" exact="prevalence" post="of psychotic disorders (such as schizophrenia, delirious disorder) among"/>
 <result pre="inclusion criteria were used, as only patients under a psychiatric" exact="treatment" post="were considered eligible. Our study confirms findings showing that"/>
 <result pre="found widely in group B patients. In contrast, patients in" exact="treatment" post="with anxiolytics/antidepressants were significantly older than those in group"/>
 <result pre="consequently presented a higher FIB-4 score at baseline, a higher" exact="prevalence" post="of cirrhosis, and a higher number of subjects previously"/>
 <result pre="characterizing psychotic disorders, probably not completely compensated by the antipsychotic" exact="treatment" post="(disorganized behavior, impaired ability of sustained attention). In fact,"/>
 <result pre="ruled out the possibility that, although patients received an appropriate" exact="treatment" post="regimen, the highest proportion of HCV genotype 3 contributed"/>
 <result pre="which was also described the unique relapse (Y93H, NS5A at" exact="treatment" post="failure within 12 weeks after EOT). Moreover, one of our"/>
 <result pre="main concerns before starting DAAs and during the course of" exact="treatment" post="was the need of an adjustment or modification of"/>
 <result pre="patients, in agreement with psychiatrists. In fact, changes in psychiatric" exact="treatment" post="before DAA-initiation seemed to play a role in treatment"/>
 <result pre="psychiatric treatment before DAA-initiation seemed to play a role in" exact="treatment" post="failure as it was associated with a higher number"/>
 <result pre="of a self-rated questionnaire evaluated after the completion of anti-HCV" exact="treatment" post="failed to prove whether lost to follow-up patients was"/>
 <result pre="relationship). Mostly, psychiatric drugs modifications were adopted among patients in" exact="treatment" post="with antipsychotics (up to 19% of cases); the majority"/>
 <result pre="changes should be avoided if not strictly required. Overall, DAA-based" exact="treatment" post="was safe. Almost half of patients (41.6%) experienced at"/>
 <result pre="groups) was associated with more AEs in the course of" exact="treatment" post="in comparison with patients treated with RBV-sparing regimens. Severe"/>
 <result pre="4 individuals who did not achieve EOT, 3/4 reported a" exact="treatment" post="discontinuation due to SAEs, including seizure, intense headache, angina"/>
 <result pre="of these patients to perceive the initiation of a new" exact="treatment" post="course as a stressing factor [27]. Usually, these symptoms"/>
 <result pre="on anxiety or depression during or after chronic hepatitis C" exact="infection" post="treatment, even in high-risk patients with major psychiatric disorders"/>
 <result pre="in our experience, none of the psychiatric disorders reported during" exact="treatment" post="had worsened at the end of treatment. As widely"/>
 <result pre="of subjects; another limit is the restricted follow-up period after" exact="treatment" post="and the lacking of a clinical follow-up based on"/>
 <result pre="Conclusion Our study points out the complexity of the anti-HCV" exact="treatment" post="of HCV-infected patients with psychiatric comorbidity and suggests that"/>
 <result pre="Dasabuvir EBR Elbasvir EMA European Medicines Agency EOT End of" exact="treatment" post="FDA Food and Drug Administration GLE Glecaprevir GRZ Grazoprevir"/>
 <result pre="C virus infectionClin Liver Dis20081261163610.1016/j.cld.2008.03.01218625431 4.SchaeferMCapuronLFriebeADiez-QuevedoCRobaeysGNeriSet al.Hepatitis C infection, antiviral" exact="treatment" post="and mental health: a European expert consensus statementJ Hepatol2012571379139010.1016/j.jhep.2012.07.03722878466"/>
 <result pre="– a reviewJ Adv Res2017813914810.1016/j.jare.2016.09.00528149649 7.AdinolfiLENevolaRLusGRestivoLGuerreraBRomanoCet al.Chronic hepatitis C virus" exact="infection" post="and neurological and psychiatric disorders: an overviewWorld J Gastroenterol2015212269228010.3748/wjg.v21.i8.226925741133"/>
 <result pre="disorders: an overviewWorld J Gastroenterol2015212269228010.3748/wjg.v21.i8.226925741133 8.LaceyCEllenSDevlinHWrightEMijchAHepatitis C in psychiatry inpatients:" exact="testing" post="rates, prevalence and risk behavioursAustralas Psychiatry20071531531910.1080/1039856070135811317612885 9.HosodaSTakimuraHShibayamaMKanamuraHIkedaKKumadaHPsychiatric symptoms related"/>
 <result pre="overviewWorld J Gastroenterol2015212269228010.3748/wjg.v21.i8.226925741133 8.LaceyCEllenSDevlinHWrightEMijchAHepatitis C in psychiatry inpatients: testing rates," exact="prevalence" post="and risk behavioursAustralas Psychiatry20071531531910.1080/1039856070135811317612885 9.HosodaSTakimuraHShibayamaMKanamuraHIkedaKKumadaHPsychiatric symptoms related to interferon"/>
 <result pre="Clin Neurosci20005456557210.1046/j.1440-1819.2000.00754.x11043807 10.NiederauCMaussSSchoberAStoehrAZimmermannTWaizmannMet al.Predictive factors for sustained virological response after" exact="treatment" post="with pegylated interferon α-2a and ribavirin in patients infected"/>
 <result pre="European Association for the Study of the LiverEASL recommendations on" exact="treatment" post="of hepatitis C 2018J Hepatol20186946151110.1016/j.jhep.2018.03.02629650333 12.JainMKThamerMTherapondosGShiffmanMLKshirsagarOClarkCHas access to hepatitis"/>
 <result pre="al.Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV" exact="infection" post="and psychiatric disorders: an integrated analysisJ Viral Hepat20192695196030977945 14.ChristensenSBuggischPMaussSBökerKSchottEKlinkerHet"/>
 <result pre="psychiatric disorders: an integrated analysisJ Viral Hepat20192695196030977945 14.ChristensenSBuggischPMaussSBökerKSchottEKlinkerHet al.Direct-acting antiviral" exact="treatment" post="of chronic HCV-infected patients on opioid substitution therapy: still"/>
 <result pre="concern in clinical practice?Addiction2018113586888210.1111/add.1412829359361 15.MiaronsMSánchez-UlayarASempereGMarínSCastellvíJMNew direct-acting antivirals for hepatitis C" exact="treatment" post="and neuropsychiatric symptoms in psychiatric risk groupsEur J Hosp"/>
 <result pre="psychiatric risk groupsEur J Hosp Pharm2018016 16.GayamVJegedeOTiongsonBMandalAKSidhuJGarlapatiPOutcomes of direct-acting antiviral" exact="treatment" post="of psychiatric patients with comorbid hepatitis C virus infectionDig"/>
 <result pre="elimination of hepatitis CJ Hepatol20176766566610.1016/j.jhep.2017.06.03328760329 19.LarreyDRipaultMPPageauxGPPatient adherence issues in the" exact="treatment" post="of hepatitis CPatient Prefer Adherence2014876377310.2147/PPA.S3033924920888 20.DirksMPflugradHHaagKPersistent neuropsychiatric impairment in"/>
 <result pre="brief depressionJ Affect Disord201214136136610.1016/j.jad.2012.03.02022609196 24.WuJYShaboltBTeohNBlunnAcollab: To CRodriguez-MoralesIet al.Influence of psychiatric" exact="diagnosis" post="on treatment uptake and interferon side effects in patients"/>
 <result pre="Affect Disord201214136136610.1016/j.jad.2012.03.02022609196 24.WuJYShaboltBTeohNBlunnAcollab: To CRodriguez-MoralesIet al.Influence of psychiatric diagnosis on" exact="treatment" post="uptake and interferon side effects in patients with hepatitis"/>
 <result pre="effects in patients with hepatitis CJ Gastroenterol Hepatol2014291258126410.1111/jgh.1251524955454 25.SundbergILannergårdARamklintMCunninghamJLDirect-acting antiviral" exact="treatment" post="in real world patients with hepatitis C not associated"/>
 <result pre="in patients with neuropsychiatric manifestationsAntivir Ther201823475510.3851/IMP324530451150 29.GallachMVergaraMda CostaJPMiquelMCasasMSanchez-DelgadoJet al.Impact of" exact="treatment" post="with direct-acting antivirals on anxiety and depression in chronic"/>
</results>
